Monday morning brought good news again for Americans: early data on Moderna’s COVID-19 vaccine candidate shows that it is 94.5% effective in protecting recipients from the coronavirus. The Phase 3 trial was conducted alongside the National Institutes of Health and the Biomedical Advanced Research and Development Authority with the results being observed by the Independent Data Safety Monitoring Board.
Within the next few weeks, Moderna plans to submit an Emergency Use Authorization request for the messenger RNA vaccine candidate with the Food and Drug Administration.
This positive news could not be more timely. Unfortunately, Texas has surpassed one million COVID-19 cases. While we wait for more therapeutics and vaccines, it remains paramount that we continue to follow Centers for Disease Control and Prevention guidelines to protect one another.
